Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 (CYP) 3A, inhibit CYP2C9, CYP2C19 and P‐glycoprotein (P‐gp). Herein, 2 open‐label, single‐sequence, crossover stud...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Pharmacol
Päätekijät: Zahir, Hamim, Kobayashi, Fumiaki, Zamora, Cynthia, Gajee, Roohi, Gordon, Michael S., Babiker, Hani M., Wang, Qiang, Greenberg, Jonathan, Wagner, Andrew J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Drug Interactions
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7891582/
https://ncbi.nlm.nih.gov/pubmed/32918831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1734
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia